Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: Results of a randomized trial
- 31 July 2005
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 150 (1) , 79-88
- https://doi.org/10.1016/j.ahj.2005.01.007
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarctionJournal of the American College of Cardiology, 2003
- Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial InfarctionCirculation, 2002
- Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarctionJournal of the American College of Cardiology, 2002
- Trial of Abciximab With and Without Low-Dose Reteplase for Acute Myocardial InfarctionCirculation, 2000
- Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial InfarctionCirculation, 2000
- Abciximab Facilitates the Rate and Extent of ThrombolysisCirculation, 1999
- TNK–Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial InfarctionCirculation, 1998
- TIMI Frame CountCirculation, 1996
- Hemorrhagic Events during Therapy with Recombinant Tissue-Type Plasminogen Activator, Heparin, and Aspirin for Acute Myocardial InfarctionAnnals of Internal Medicine, 1991
- Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.Circulation, 1987